Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 22;15(7):521. doi: 10.1038/s41419-024-06894-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Survival curves and log-rank (Mantel–Cox) test in MNHOC#22 bearing mice. Tumor was transplanted intraperitoneally (i.p.) and at day 8 mice were randomized to receive vehicle (-●-), olaparib (100 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (50 mg/kg p.o. 5 days a week for 4 weeks, ) and their combination (). p < 0.0023 onvansertib vs control; p < 0.0001: combo vs control and combo vs onvansertib. B Survival curves and log-rank (Mantel–Cox) test in MNHOC#266 bearing mice. MNHOC#266 PDX was transplanted i.p. and at day 8 mice were randomized to receive vehicle (-●-), olaparib (80 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (50 mg/kg p.o. 5 days a week for 4 weeks, ) and their combination () p < 0.0001: combo vs olaparib; p < 0.0001: combo vs control; p < 0.0069 combo vs onvansertib. C, D MNHOC#218Ola xenografts were transplanted subcutaneously and grown until masses reached 100–150 mg. Mice were then randomized to receive vehicle (-●-), olaparib (80 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (30 mg/kg in C or 45 mg/kg in D p.o. 5 days a week for 4 weeks, ), and their combination (). Data are the mean ± SEM of tumor masses, as described in Materials and Methods; each group consisted of 8 animals. Gray dashed lines represent treatment duration.

Inline graphic — A Survival curves and log-rank (Mantel–Cox) test in MNHOC#22 bearing mice. Tumor was transplanted intraperitoneally (i.p.) and at day 8 mice were randomized to receive vehicle (-●-), olaparib (100 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (50 mg/kg p.o. 5 days a week for 4 weeks, ) and their combination (). p < 0.0023 onvansertib vs control; p < 0.0001: combo vs control and combo vs onvansertib. B Survival curves and log-rank (Mantel–Cox) test in MNHOC#266 bearing mice. MNHOC#266 PDX was transplanted i.p. and at day 8 mice were randomized to receive vehicle (-●-), olaparib (80 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (50 mg/kg p.o. 5 days a week for 4 weeks, ) and their combination () p < 0.0001: combo vs olaparib; p < 0.0001: combo vs control; p < 0.0069 combo vs onvansertib. C, D MNHOC#218Ola xenografts were transplanted subcutaneously and grown until masses reached 100–150 mg. Mice were then randomized to receive vehicle (-●-), olaparib (80 mg/kg p.o. 5 days a week for 4 weeks, ), onvansertib (30 mg/kg in C or 45 mg/kg in D p.o. 5 days a week for 4 weeks, ), and their combination (). Data are the mean ± SEM of tumor masses, as described in Materials and Methods; each group consisted of 8 animals. Gray dashed lines represent treatment duration.